Incannex Healthcare Inc.IXHL
Price (close)
$3.40
Market cap
$40.7M
P/E
—
Revenue (TTM)
$86,000
Net income
-$48.4M
Dividend yield
—
1-year total return
-81.0%
Net margin
—
Revenue growth
—
Debt / equity
0.02x
What Incannex Healthcare Inc. does.
dedicated to developing innovative medicines for patients living with serious chronic diseases and significant unmet needs.
2/3 clinical trial for the treatment of obstructive sleep apnea (“OSA”) is an oral fixed-dose combination of dronabinol and
acetazolamide designed to act synergistically by targeting two different physiological pathways associated with the intermittent hypoxia
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $604,884 | $1.9M | — | — | $12,000 | $86,000 |
| Net income | -$4.7M | -$11.4M | -$14.9M | -$48.8M | -$18.5M | -$46.9M |
| Free cash flow | — | — | — | -$11.1M | -$16.1M | -$12.5M |
More on IXHL.
- Incannex Healthcare Inc. summary
- Incannex Healthcare Inc. financial statements
- Incannex Healthcare Inc. key metrics
- Incannex Healthcare Inc. health scores and style box
- Incannex Healthcare Inc. earnings
- Incannex Healthcare Inc. dividends
- Incannex Healthcare Inc. valuation
- Incannex Healthcare Inc. ownership and insiders
- Incannex Healthcare Inc. peers
Figures from Incannex Healthcare Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.